Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

CoreAge Rx vs Gala Health

Two GLP-1 providers, one scoreboard. We put CoreAge Rx and Gala Health head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 1 · Grade A

CoreAge Rx

Visit CoreAge Rx Full brief →
vs
No. 29 · Grade B−

Gala Health

Visit Gala Health Full brief →

The verdict

CoreAge Rx takes this head-to-head.

CoreAge Rx scores 94 to 82 on our six-factor Brief Score — One price on both molecules that does not climb as you titrate — but the headline $99 and $149 are annual-plan rates, paid in full up front.

That doesn't make Gala Health a bad call — it's best for readers ready to commit to a year of compounded tirzepatide up front, who want it available in all 50 states and like knowing a brand-name ozempic route exists if they ever switch — and who value a menopause/hrt program alongside the glp-1. Weigh the six factors below against your own priorities before you decide.

Why CoreAge Rx leads: it's our #1 here — one flat, no-step-up price on both molecules, nationwide, and the steadiest line on our tracker.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both providers scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
97
78
Supply Reliability
95
84
Transparency
90
74
Access Breadth
93
90
Clinical Oversight
92
85
Track Record
88
82
CoreAge RxBrief Score 94 · 82Gala Health

Price, coverage & the tracker

CoreAge RxGala Health
Brief Score94/100 (A)82/100 (B−)
Semaglutide$99/mo only on a 12-month plan paid in full ($1,188 in one charge); month-to-month rate not publishedCompounded semaglutide is included in the same From $179/mo yearly-subscription plan; brand-name Ozempic from $1,299/mo cash
Tirzepatide$149/mo only on a 12-month plan paid in full ($1,788 in one charge); month-to-month rate not publishedFrom $179/mo only on the yearly subscription; $199/mo on the 3-month plan (all doses included)
CoverageUS only; restrictions by state, confirmed at intakeAll 50 states
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyInjection only
On the trackerStableprice stableStableprice stable

CoreAge Rx: Headline unchanged for a third straight cycle. The $99 and $149 are the 12-month prepay rates; CoreAge publishes no month-to-month price.

Gala Health: Headline compounded-tirz rate unchanged this cycle, but it is a yearly-subscription price — the shortest published plan is three months at $199/mo, and no month-to-month rate exists.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.